HS-10296
Phase 2Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10296 is one of 25 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
REGN2810
RegeneronPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
HS-10296
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
First-line Treatment1 trial
Non-Small Cell Lung Cancer1 trial
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04685070·56 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10296. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details